505 related articles for article (PubMed ID: 25394774)
1. TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.
Croucher JL; Iyer R; Li N; Molteni V; Loren J; Gordon WP; Tuntland T; Liu B; Brodeur GM
Cancer Chemother Pharmacol; 2015 Jan; 75(1):131-41. PubMed ID: 25394774
[TBL] [Abstract][Full Text] [Related]
2. Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model.
Iyer R; Wehrmann L; Golden RL; Naraparaju K; Croucher JL; MacFarland SP; Guan P; Kolla V; Wei G; Cam N; Li G; Hornby Z; Brodeur GM
Cancer Lett; 2016 Mar; 372(2):179-86. PubMed ID: 26797418
[TBL] [Abstract][Full Text] [Related]
3. AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts.
Iyer R; Varela CR; Minturn JE; Ho R; Simpson AM; Light JE; Evans AE; Zhao H; Thress K; Brown JL; Brodeur GM
Cancer Chemother Pharmacol; 2012 Sep; 70(3):477-86. PubMed ID: 22623209
[TBL] [Abstract][Full Text] [Related]
4. Effect of CEP-751 (KT-6587) on neuroblastoma xenografts expressing TrkB.
Evans AE; Kisselbach KD; Liu X; Eggert A; Ikegaki N; Camoratto AM; Dionne C; Brodeur GM
Med Pediatr Oncol; 2001 Jan; 36(1):181-4. PubMed ID: 11464878
[TBL] [Abstract][Full Text] [Related]
5. Trk inhibitor attenuates the BDNF/TrkB-induced protection of neuroblastoma cells from etoposide in vitro and in vivo.
Li Z; Zhang Y; Tong Y; Tong J; Thiele CJ
Cancer Biol Ther; 2015; 16(3):477-83. PubMed ID: 25700942
[TBL] [Abstract][Full Text] [Related]
6. Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma.
Iyer R; Evans AE; Qi X; Ho R; Minturn JE; Zhao H; Balamuth N; Maris JM; Brodeur GM
Clin Cancer Res; 2010 Mar; 16(5):1478-85. PubMed ID: 20179224
[TBL] [Abstract][Full Text] [Related]
7. [Effects of tyrosine kinase receptor B and brain-derived neurotrophic factor on chemoresistance in neuroblastoma].
Li AM; Zhang JH; Zhang JH; Zhang KR; Rong DJ
Zhonghua Er Ke Za Zhi; 2006 Jul; 44(7):535-9. PubMed ID: 17044982
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition.
Zhang L; Scorsone K; Woodfield SE; Zage PE
Cancer Chemother Pharmacol; 2015 Nov; 76(5):977-87. PubMed ID: 26407819
[TBL] [Abstract][Full Text] [Related]
9. New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.
Di Paolo D; Yang D; Pastorino F; Emionite L; Cilli M; Daga A; Destafanis E; Di Fiore A; Piaggio F; Brignole C; Xu X; Liang C; Gibbons J; Ponzoni M; Perri P
Oncotarget; 2015 Oct; 6(30):28774-89. PubMed ID: 26299615
[TBL] [Abstract][Full Text] [Related]
10. Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3'-kinase pathway.
Jaboin J; Kim CJ; Kaplan DR; Thiele CJ
Cancer Res; 2002 Nov; 62(22):6756-63. PubMed ID: 12438277
[TBL] [Abstract][Full Text] [Related]
11. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
12. Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.
DuBois SG; Marachelian A; Fox E; Kudgus RA; Reid JM; Groshen S; Malvar J; Bagatell R; Wagner L; Maris JM; Hawkins R; Courtier J; Lai H; Goodarzian F; Shimada H; Czarnecki S; Tsao-Wei D; Matthay KK; Mosse YP
J Clin Oncol; 2016 Apr; 34(12):1368-75. PubMed ID: 26884555
[TBL] [Abstract][Full Text] [Related]
13. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
[TBL] [Abstract][Full Text] [Related]
14. PI3K Inhibitor Combined With Chemotherapy Can Enhance the Apoptosis of Neuroblastoma Cells In Vitro and In Vivo.
Geng X; Xie L; Xing H
Technol Cancer Res Treat; 2016 Oct; 15(5):716-22. PubMed ID: 26224681
[TBL] [Abstract][Full Text] [Related]
15. Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models.
Cai W; Maldonado NV; Cui W; Harutyunyan N; Ji L; Sposto R; Reynolds CP; Keshelava N
Br J Cancer; 2010 Oct; 103(9):1369-79. PubMed ID: 20924375
[TBL] [Abstract][Full Text] [Related]
16. GZD2202, a novel TrkB inhibitor, suppresses BDNF-mediated proliferation and metastasis in neuroblastoma models.
Zou J; Zhang Z; Xu F; Cui S; Qi C; Luo J; Wang Z; Lu X; Tu Z; Ren X; Song L; Ding K
J Drug Target; 2019 Apr; 27(4):442-450. PubMed ID: 30301369
[TBL] [Abstract][Full Text] [Related]
17. Resistance to chemotherapy mediated by TrkB in neuroblastomas.
Ho R; Eggert A; Hishiki T; Minturn JE; Ikegaki N; Foster P; Camoratto AM; Evans AE; Brodeur GM
Cancer Res; 2002 Nov; 62(22):6462-6. PubMed ID: 12438236
[TBL] [Abstract][Full Text] [Related]
18. The selective Trk inhibitor AZ623 inhibits brain-derived neurotrophic factor-mediated neuroblastoma cell proliferation and signaling and is synergistic with topotecan.
Zage PE; Graham TC; Zeng L; Fang W; Pien C; Thress K; Omer C; Brown JL; Zweidler-McKay PA
Cancer; 2011 Mar; 117(6):1321-91. PubMed ID: 20960503
[TBL] [Abstract][Full Text] [Related]
19. Effects of quercetin combined with anticancer drugs on metastasis-associated factors of gastric cancer cells: in vitro and in vivo studies.
Lei CS; Hou YC; Pai MH; Lin MT; Yeh SL
J Nutr Biochem; 2018 Jan; 51():105-113. PubMed ID: 29125991
[TBL] [Abstract][Full Text] [Related]
20. Small molecule inhibitor agerafenib effectively suppresses neuroblastoma tumor growth in mouse models via inhibiting ERK MAPK signaling.
Li H; Yu Y; Zhao Y; Wu D; Yu X; Lu J; Chen Z; Zhang H; Hu Y; Zhai Y; Su J; Aheman A; De Las Casas A; Jin J; Xu X; Shi Z; Woodfield SE; Vasudevan SA; Agarwal S; Yan Y; Yang J; Foster JH
Cancer Lett; 2019 Aug; 457():129-141. PubMed ID: 31100410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]